Empirical Study Of Subcutaneous Injection Of CD147siRNA Into The Psoriatic Lesions In A SCID-hu Xenogeneic Transplantation Model

ObjectiveInvestigate the effects of subcutaneous injection of CD147siRNA into the psoriatic lesions in a SCID-hu xenogeneic transplantation model.MethodsPsoriatic lesions were obtained from 8 patients with plaque psoriasis and transplanted onto the back of the SCID mice. Ten days after the transplantation, SEB-stimulated PBMCs (approximately 1×10~6 cells in 0.1 mL of RPMI 1640 medium for each mouse) were injected subcutaneously into the grafted skin to establish a SCID-hu xenogeneic transplantation model. Totally, 32 SCID mice were divided into four groups, and precollagen encapsulated CD147siRNA, the control nonspecific CD147siRNA, or 0.9% normal saline were injected subcutaneously into the grafts of the individual group, respectively. Changes of the grafts were observed macrographically as well as histopathogically with HE staining, and the expression of Ki67 and CD3 was detected with immunohistochemistry.Results1. After two weeks of transplantion, grafts grow well and most of them maintained the psoriatic clinical and histopathological characteristics. 2. After subcutaneous injection of CD147siRNA into psoriatic grafts, the histological score was decreased significantly (P < 0.01), and the expression of Ki67 and CD3 were markedly reduced as compared to the control groups (P < 0.05).Conclusion1. A human psoriasis skin-SCID mouse model was successfully established.2. Local therapeutic efficacy of subcutaneous injection of CD147siRNA into the psoriatic grafts in the SCID-hu xenogeneic transplantation model was achieved.